Portola Pharmaceuticals has signed a $50 million loan agreement with Bristol-Myers Squibb and Pfizer that gives Portola supplementary funds to allow for the development and clinical trials of AndexXa. Read More »

Imprimis Pharmaceuticals and Focus Script have collaboratively launched the Correct Compound program, which provides a customizable formulary through the CDF-Logic program as a specialized compound pharmacy care solution. Read More »

Shionogi & Co. Ltd., its subsidiary Shionogi Inc. and Purdue Pharma will launch Symproic, also known as naldemedine, to treat adult patients with chronic non-cancer pain who have opioid-induced constipation. Read More »

Integrated Delivery Networks are continuing to form with the continued growth and mergers of health systems. Read More »

Profounda's miltefosine has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »

Profounda's miltefosine has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of Acanthamoeba Keratitis. Read More »

Ionis Pharmaceuticals posted earnings of $28 million from AstraZeneca due to the finalization of AstraZeneca’s studies supporting IND and the licensing of IONIS-KRAS-2.5Rx, also known as AZD4785. Read More »

Eli Lilly and Co., along with Incyte Corp., have announced that baricitinib received a positive opinion as well as a recommendation for approval from the European Medicines Agency Committee for Medicinal Products for Human Use. Read More »

According to a report published in the most recent issue of the Journal of the American Medical Association, scientists were able to determine that 6 percent of pregnancies after contracting the Zika virus infection resulted in one or more birth defects linked to Zika using data from the U.S. Zika Pregnancy Registry. Read More »

CVS Health recently held its annual Analyst Day, a meeting in which the discussions of strategies for long-term growth will be driven and shareholder value were held. Read More »

The results of a new study conducted by AARP show that pharmaceutical prices for brand name products has increased drastically. Read More »

Endo International subsidiary Par Pharmaceutical has begun the shipping process for ezetimibe 10 mg tablets, which is the generic form of ZETIA, developed by Merck. Read More »

EMD Serono, subsidiary of Merck KGaA, has appointed Brian Barry as its chief compliance officer with oversight of the development and execution of EMD Serono’s comprehensive compliance program. Read More »

Legislators in Missouri will move in the next session to bring the state into line with most of the rest of the country by heightening the standard on expert witness testimony in civil trials. Read More »

Protagen AG has launched NavigAID SSc, its disease stratification assay that was developed to assist pharmaceutical and biotechnology companies with their efforts to develop drugs to treat Systemic Sclerosis. Read More »

Bayer's supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECT Navigator has been accepted by the U.S. Food and Drug Administration. Read More »

Castle Creek Pharmaceuticals' exclusive license agreement for the rights to Arlevert in the United States has been finalized. Read More »

Express Scripts' enhancements have been applied to its SafeGuardRx programs, which focus on the treatment of hepatitis C and cancer. Read More »

AcelRx Pharmaceuticals has submitted a New Drug Application for ARX-04 (sufentanil sublingual tablet, 30 mcg) to the U.S. Food and Drug Administration. Read More »

aTyr Pharma has released results of its exploratory clinical trials designed to evaluate the safety and potential activity of Resolaris in treating LGMD2B and FSHD. Read More »